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Since 1995, a myriad of mutations in the genes coding for cardiac ion channel subunits or proteins interacting with 
ion channels were described in patients with inherited forms 
of arrhythmic disorders, such as congenital long QT syndrome 
(LQTS), Brugada syndrome (BrS), and catecholaminergic 
polymorphic ventricular tachycardia (CPVT), hence, defin-
ing cardiac genetic channelopathies. Most of these disorders 
have demonstrated a broad genetic and phenotypic heteroge-
neity. SCN5A is the gene encoding the pore-forming subunit, 
Na
v
1.5, mediating the Na+ current (INa) of cardiac cells. The 
arrhythmic phenotypes linked to the mutations in SCN5A are 
variable, including LQTS type 3, BrS, many forms of conduc-
tion defects, atrial fibrillation, sudden infant death syndrome, 
and dilated cardiomyopathy.1 More recently, 3 studies2–4 have 
reported on a new SCN5A-dependent clinical presentation 
called multifocal ectopic Purkinje-related premature contrac-
tions caused by the mutation p.R222Q.
Clinical Perspective on p 781
Premature ventricular complexes (PVCs) emerging at rest 
in a structurally normal heart are usually considered harm-
less,5 whereas PVCs provoked by sympathetic stimulus, such 
as physical exercise, are regarded as significant finding, neces-
sitating further evaluation. In a proportion of cases, PVCs 
indicate a risk for lethal ventricular tachycardia or fibrillation. 
Exercise-induced PVCs, bigeminy, and ventricular tachycar-
dias in structurally normal hearts, characteristic for CPVT, 
associate with considerable mortality.6–8 In fact, lethal arrhyth-
mias may occur in CPVT even before diagnostic exercise-
induced symptoms can be verified.9
The purpose of this study was to identify the genetic and func-
tional determinants underlying exercise-induced polymorphic 
ventricular arrhythmia present in a large multigenerational family. 
Using whole exome sequencing, a novel SCN5A mutation with 
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strong cosegregation with the symptomatic patients was found. 
Functional and computational studies suggest that the mutation-
induced biophysical alterations lead to atrial, Purkinje cells, and 
ventricular hyperexcitability. These findings further expand the 
spectrum of cardiac arrhythmias caused by SCN5A variants.
Methods
A Finnish family with 37 living members in 4 generations was evalu-
ated (Figure 1). Altogether 31 family members underwent cardio-
logical examination, including electrocardiographic tests and cardiac 
ultrasonography between years 2002 and 2003. In 2013, at the end 
of the follow-up period, all family members were recontacted and 
invited for assessment of their symptoms and possible cardiovascular 
interventions. Informed consent was obtained from all patients. The 
study was performed in accordance with the Helsinki Declaration and 
was approved by the local ethical review board.
Electrocardiographic and Ultrasonographic 
Examinations
Standard ECG was recorded at rest (50 mm/s, 0.1 mV/mm). QT in-
terval was measured from lead II and adjusted for heart rate (QTc) 
according to the Fridericia’s correction formula. Bicycle ergometer 
test was performed with continuous 12-lead ECG recording. The ini-
tial load was 30 W, followed by increments of 15 W each minute. 
The total number of PVCs and the maximum number of consecutive 
PVCs in ventricular salvoes were counted during work phase.
A 24-hour ambulatory ECG was recorded on an outpatient ba-
sis. Rhythm, mean heart rate, number of ventricular premature 
complexes, and number and maximum length of ventricular tachy-
cardias (≥3 consecutive ventricular complexes) were calculated. 
Echocardiography was performed using parasternal long- and 
short-axis and apical 4-chamber views. Aortic root dimension was 
measured at the sinus valsalva level. Left ventricular dimensions 
and wall thickness were measured from the M-mode recordings. 
Doppler echocardiography was used to exclude any valvular steno-
sis or regurgitation.
Phenotypic Classification of Family Members
Patients with ≥50 polymorphic PVCs or >10 polymorphic PVCs per 
minute or ventricular tachycardia during exercise stress test (ET) 
were considered affected. Individuals who were unable to perform an 
ET were classified as unknown.
Figure 1. The Nav1.5 p.I141V mutation. A, The pedigree, phenotypes, and mutation status of family members. The presence of ≥50 pre-
mature ventricular complexes (PVC) during an exercise stress test (ET) is indicated by a symbol with a half-filled left-side, the presence of 
ectopic atrial rhythm is indicated by a filled upper right quadrant and atrial fibrillation by a filled lower right quadrant. A white symbol indi-
cated normal ECG, whereas individuals without ET are indicated with a grey symbol. The presence of the I141V mutation is specified by 
a + or −. B, Targeted sequencing confirmed a heterozygous missense mutation, chr3:38,663,952 T->C, cosegregating with multiple PVCs 
during ET. Representative traces from 4 of the sequenced family members are shown. C, Multiple protein sequence alignments showing 
the conservation of isoleucine at codon 141 of the Nav1.5 protein in different vertebrate species. D, A schematic picture of the Nav1.5 pro-
tein structure, indicating the location of the I141V-mutation in domain I.
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Sequencing of Candidate Genes
Mutations in RYR2 were excluded by sequencing its all translated 
exons and exon-intron boundaries in the DNA sample of the proband 
(AMC, University of Amsterdam, Netherlands).
Whole exome sequencing of 8 affected pedigree members was per-
formed using the NimbleGen SeqCapEZ sequence capture technology 
(www.nimblegen.com/products/seqcap/ez/index.html). The exome 
targets of the patients’ DNA were captured with the NimbleGen 
SeqCap Ez Human Exome Library v2.0, followed by sequencing 
with the Illumina Genome Analyzer-IIx platform at the Technology 
Center at the Institute for Molecular Medicine Finland. The align-
ment to human reference genome hg19 and variant calling of chromo-
somal regions with a sequence-coverage of ≥9× was performed using 
the variant calling pipeline of the Institute for Molecular Medicine 
Finland.10 The data were filtered to capture only rare coding vari-
ants, that is, variants giving rise to missense, nonsense, splice site, 
or frame shift mutations either with minor allele frequencies <0.005 
or not at all present in the 1000 genomes catalogue of human genetic 
variation (http://browser.1000genomes.org/index.html).The pres-
ence of a chr3:38,663,952 T->C variant in the SCN5A gene, initial-
ly identified by exome sequencing, was assessed in all affected and 
unaffected family members by direct Sanger sequencing using for-
ward primer 5'TACTCACTCGACATACTTGG 3' and reverse primer 
5'CTTGGAGACCCTGTTTATTG 3'. The sequencing reactions were 
run on an Applied Biosystems 96-capillary 3730xl DNA Analyzer and 
analyzed with the Variant Reporter software (Applied Biosystems, 
US) at the Technology Center at the Institute for Molecular Medicine 
Finland. The predicted effect of the rare coding SCN5A variant iden-
tified was analyzed by PolyPhen2 (http://genetics.bwh.harvard.edu/
pph2/) and SIFT (http://sift.jcvi.org/).
Microsatellite Genotyping
Genome-wide linkage mapping was performed using ABI PRISM 
Linkage mapping Set MD10 (Applied Biosystems). Standard PCR 
protocols were used for amplification of microsatellite fragments us-
ing 10 ng of genomic DNA as a template. The fluorescently labeled 
PCR products were separated using ABI3730 (Applied Biosystems) 
automated electrophoresis system and the genotype calls were made 
using GeneMapper3.7 software. Two independent reviewers veri-
fied all allele calls, and any discrepancies were resolved. Genotypes 
were checked for violation of Mendelian segregation of alleles us-
ing PEDCHECK.11
Linkage Analysis
Linkage analysis using exercise-induced frequent polymorphic ven-
tricular premature complexes during an exercise test as a dichoto-
mized trait was performed using the program Merlin (http://www.
sph.umich.edu/csg/abecasis/merlin/index.html). The analyses were 
run applying an affected-only approach in which the phenotype of 
all unaffected family members was assumed be unknown, and the 
disease allele frequency was set to 0.0001.
Site-Directed Mutagenesis
Site-directed mutagenesis was performed on pCDN3.1-hSCN5A us-
ing the Quick-Change II XL site-directed mutagenesis kit (Stratagene) 
according to the manufacturer’s instructions. The construct was com-
pletely sequenced to ensure that there was no other mutation present.
Cell Culture
Human embryonic kidney 293 cells were cultured at 37°C in Dulbecco’s 
Modified Eagle Medium supplemented with 10% Fetal bovine serum, 
4 mmol/L glutamine, and 20 mg/mL gentamicin in a humidified atmo-
sphere of 5% CO2 and 95% air. All cell medium components, except 
glutamine (Sigma-Aldrich), were purchased from Gibco.
Cellular Electrophysiology
The human embryonic kidney 293 cells were transfected with 
DNA complexed to JetPEI (Polyplus-transfection) according to 
the manufacturer’s instructions. DNA concentrations were 1 μg of 
pCDN3.1-Na
v
1.5 wild type (WT), p.I137V, or p.I141V and 1 μg of 
pIRES-hβ1-CD8. The resulting Na
v
1.5 protein is a splice variant 
lacking a glutamine at position 1077 (Q1077del). Eight hours after 
transfection, the cells were isolated and seeded in plastic Petri dishes 
at low density. Twenty-four hours after transfection, the resulting so-
dium current (INa) was recorded at room temperature (23–25°C) under 
whole-cell voltage clamp conditions with an Axopatch 200B (Axon 
Instruments, Inc) amplifier interfaced to a personal computer and 
driven by the PClamp 10 software (Molecular Devices Corporation). 
Capacitance and series resistances were compensated (60% to 80% 
compensation), and the residual capacitive currents were cancelled 
using a P/4 protocol. The cells were bathed with an extracellular solu-
tion containing (in mmol/L) NaCl 50, NMDG-Cl 80, CsCl 5, MgCl2 
1.2, CaCl2 2, HEPES 10, and glucose 5. The pH was adjusted to 7.4 
with CsOH. Glass pipettes (tip resistance, 1.5–3 mol/LΩ) were filled 
with an intracellular medium containing (in mmol/L) CsCl 60, aspar-
tic acid 50, CaCl2 1, MgCl2 1, HEPES 10, EGTA 11, and Na2ATP 5. 
pH was adjusted to 7.2 with CsOH. For the window current measure-
ments, the presented recordings are normalized to the peak current 
obtained at −20 mV and are tetrodotoxin (TTX)-subtracted (30 μM).
All products were purchased from Sigma, except TTX, which was 
obtained from Alomone.
Computer Simulations of INa, Action  Potentials (AP), 
and Conduction
The INa and action potentials were simulated using the 10 Tusscher–
Noble–Noble–Panfilov (TNNP) human ventricular cell model,12 
the Courtemanche–Ramirez–Nattel human atrial cell model,13 and 
the Stewart–Aslanidi–Noble–Noble–Boyett–Zhang Purkinje cell 
model.14 In all 3 models, INa is represented according to a Hodgkin–
Huxley formalism, INa=gNamaxm3hj(Vm–ENa), where gNamax is the 
maximal conductance of INa, m3 represents 3 activation gates, h and j are inactivation gates, V
m
 is the membrane potential, and ENa is the 
Nernst potential of sodium. The INa formulation in the TNNP and 
Stewart–Aslanidi–Noble–Noble–Boyett–Zhang models, which are 
based on human INa recordings, are equivalent up to the maximal con-
ductance of INa, but they differ in terms of steady state values and 
time constants of the different gates from the INa formulation in the 
Courtemanche–Ramirez–Nattel model, which is based on that of Luo 
and Rudy.15 Table 1 presents the modications of INa that were intro-
duced in the 3 models to match the experimental data.
Action potential propagation was simulated in a 1 cm long fiber 
based on the equation
∂ ∂ = − + ∂ ∂V t I D V Xm ion m
2 2 ,
where Iion is the sum of the ionic currents normalized to cell capaci-
tance and D is the diffusion constant, which depends on intra- and 
intercellular conductance and surface-to-volume ratio. For all 3 mod-
els, D was set to 0.00154 cm2/ms as in the original TNNP model,12,16 
which corresponds to the normal level of gap junctional coupling in 
the direction of myocardial fibers. Using the same D allows a direct 
comparison of conduction between the 3 models. Gating variables 
were integrated using the method of Rush and Larsen and the other 
model variables using the forward Euler algorithm, with Δx=0.01 cm 
and Δt=0.005 ms. The fiber was stimulated at 1 extremity and con-
duction velocity was computed using linear regression of activation 
times (occurrence of dV/dt
max
) over a segment extending from 25% 
to 75% of fiber length. Of note, the computer simulations have the 
limitation that the models did not incorporate the effects of adrenergic 
stimulation. Of note, in the current study, we did not incorporate any 
variability in the computer simulations. All the used values are the 
arithmetic means of the given parameters.
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Data Analysis and Statistical Methods
Currents were analyzed with Clampfit software (Axon Instruments, 
Inc). Data were analyzed using a combination of pClamp10, Excel 
(Microsoft), and Prism (graphpad).
Comparisons between groups were performed with 2-tailed 
Student’s t test or ANOVA for normally distributed parameters. The 
Kolmogorov–Smirnov test was used to test the normality of the ana-
lyzed experimental data. Data are expressed as mean±SD. A P value 
<0.05 was considered significant.
Results
The structure of the Finnish family segregating the exercise-
induced arrhythmia syndrome is shown in Figure 1A, and the 
findings of the electrocardiographic and cardiac ultrasonog-
raphy studies are presented in Table 2. Of those alive in the 
4-generation family, a total of 6 individuals had experienced 
a syncopal spell. One case of sudden cardiac death occurred 
during prospective follow-up. Family member II-1 had died at 
the age of 2 years. None of the family members had a docu-
mented coronary artery disease or a history of angina pectoris.
ECG Registrations
Of 16 adult Na
v
1.5 p.I141V mutation carriers, 5 presented with 
sinus rhythm, 1 with atrial flutter, and 11 with ectopic atrial 
rhythm in their resting ECG (Table 2; Figure 2A and 2B). Nodal 
escape rhythm was seen occasionally (Figure 2C). PVCs were 
not present in resting ECG in any of the family members at first 
examination. The sinus rate at rest was higher in Na
v
1.5 p.I141V 
mutation carriers than in noncarriers (Table 3). PQ and QTfc 
intervals, QRS complex morphology and duration, ST segment, 
and T-wave pattern were normal in all during sinus rhythm.
A total of 32 subjects were studied by repeated ETs. The 
first ET showed ≥50 PVCs during exercise in 10 and the sub-
sequent ETs revealed the same in 3 additional individuals, all 
carriers of Na
v
1.5 p.I141V mutation. During the ETs, the ven-
tricular arrhythmias progressively became more complex and 
abundant in parallel with the increasing sinus rate; examples 
are shown in Figure 2D and 2E. Some of the QRS complexes 
show varying morphology. In 9 out of 13 ET-positive subjects, 
arrhythmia progressed to nonsustained polymorphic ventricu-
lar tachycardia (≥3 successive complexes; Figure 2F). The 
average sinus rate at which the ventricular arrhythmias ini-
tially appeared was 99±17 beats per minute, and arrhythmias 
disappeared rapidly after discontinuation of exercise. The 
maximum sinus rate achieved during exercise was on average 
97%±8% of the age-specific maximum.
Cardiac Ultrasonography
In cardiac ultrasonography, all Na
v
1.5 p.I141V mutation carri-
ers showed normal left ventricular end-diastolic diameter and 
index (48±3 mm and 24.5±2.8 mm/m2, respectively). Aortic 
root diameter was ≥44 mm in 3 of them.
Detection of the SCN5A Mutation
By using whole exome sequencing, we detected a novel mis-
sense mutation, (chr3:38,663,952 T->C) in SCN5A, encod-
ing for the Na
v
1.5 sodium channel protein, in addition to 2 
rare coding mutations, that is, rs148604148 (missense, MAF 
0.002) in XYLB, encoding for xylulokinase homolog (H. 
influenzae) and rs141040660 (synonymous, MAF 0.0005) 
in ANO10, encoding for anoctamin 10, that were shared by 
all 8 sequenced individuals. The 3 genes are located at 5 Mb 
distance from each other on chromosome 3p22.2, but only 
SCN5A is expressed in cardiac tissue and is known to be asso-
ciated with several arrhythmia disorders, including congenital 
LQTS type 3, BrS, and idiopathic ventricular fibrillation.
Because the exome sequencing resulted in low cover-
age across chr3:38,663,952, ie, 3× to 9×, the initial analyses 
showed the presence of the chr3:38,663,952 T->C variant in 
7 out of 8 analyzed affected family members. Nonetheless, 
targeted sequencing of the complete family showed that all 13 
affected pedigree members in addition to 4 unaffected fam-
ily members and 3 children with unknown phenotype carried 
the chr3:38,663,952 T->C mutation (representative sequence 
traces from 4 family members are presented in Figure 1B). 
Based on PolyPhen2 and SIFTanalyses, the mutation, which 
results in an isoleucine to valine substitution at position 141 
of the Na
v
1.5 protein (p.I141V), was classified as possibly 
damaging with a score of 0.46 and deleterious with a score 
of 0.00, respectively. Moreover, the mutation seems to be 
unique to this family. It is not present in the published 1000 
genomes data set, of which 83 are Finnish subjects, neither 
was it present in exome sequence data from 580 unrelated 
Finnish subjects (unpublished observation), further indicating 
that this sequence variant is rare. Finally, we performed link-
age analyses to assess the probability that all affected indi-
viduals share a mutation. The chr3:38,663,952 T->C variant 
yielded a 2-point LOD-score of 3.56 (conservatively classify-
ing only individuals with >50 exercise-induced polymorphic 
complexes as affected), whereas genome-wide linkage analy-
ses of the whole pedigree utilizing microsatellite genotypes 
indicated that the chr3:38,663,952 T->C variant resided in the 
only chromosomal region displaying complete cosegregation 
with the arrhythmia phenotype. No mutations were found in 
the genes RYR2 and CASQ2.
Table 1. Formulation of the m and h Gates for the I141V 
Mutant INa
LR-CRN I
Na
  
model (16,17)
TNNP/SANNBZ I
Na
  
model (15)
m∞,p.I141V(Vm)=m∞,WT(Vm−σa) m∞,p.I141V (Vm)=m∞,WT(Vm−σa)
τ
m,p.I141V
 (V
m
)=τ
m,WT
(V
m
−σ
a
) τ
m,p.I141V
 (V
m
)=τ
m,WT
(V
m
−σ
a
)
β
h,p.I141V
 (V
m
)=β
h,WT
(V
m
−σ
i
) h∞,p.I141V (Vm)=h∞,WT(Vm)
α
h,p.I141V
 (V
m
)=α
h,WT
(V
m
) β
h,p.I141V
 (V
m
)=β
h,WT
(V
m
−σ
i
)
For both genotypes α
h,p.I141V
 (V
m
)=α
h,WT
(V
m
)
h∞(Vm)=αh(Vm)/(αh(Vm)+βh(Vm)) For both genotypes
τ
h
(V
m
)=1/(α
h
(V
m
)+β
h
(V
m
)) τ
h
(V
m
)=α
h
(V
m
)1/(α
h
(V
m
)+β
h
(V
m
))
For both models
σ
a
=–7 mV
σ
i
=–7 mV
dm/dt=(m∞(Vm)−m)/τm
dh/dt=(h∞(Vm)−h)/τh
WT denote the formulation of the original models. The shift parameters σ
a
 
and σ
i
 were determined based on experimental data.
CRN, Courtemanche–Ramirez–Nattel; SANNBZ, Stewart–Aslanidi–Noble–
Noble–Boyett–Zhang; TNNP, Tusscher–Noble–Noble–Panfilov; and WT, wild type.
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Effects of p.I141V Mutation on Na
v
1.5 Channel 
Function in Human Embryonic Kidney 293 Cells
To investigate the functional consequences of the p.I141V 
mutation on the Na+ channel activity, we used the whole-cell 
configuration of the patch-clamp technique. The presence of 
the mutation did not modify the Na+ current density (Table A 
in the Data Supplement). The voltage-dependence of steady 
state activation was shifted toward more negative potentials 
(−7 mV) in the presence of the mutation (P<0.01; Figure 3A 
and 3B; Table A in the Data Supplement). For a given com-
mand voltage, the activation and inactivation kinetics were 
accelerated in the mutant channel (Figure 3C and 3D). How-
ever, no significant differences were observed regarding the 
voltage dependence of steady state inactivation (Figure 3B; 
Table A in the Data Supplement), the recovery from fast inac-
tivation (Figure 3E), and the onset and recovery from slow 
inactivation (Figure IA and IB in the Data Supplement).
Based on the negative shift of the steady state activation 
curve, we predicted an increase of the window sodium current 
(Figure 3B, inset). To investigate this window current, we 
examined the responses of cells transfected with Na
v
1.5 WT 
and p.I141V channels to a ramp voltage protocol, in which 
membrane potential was gradually changed between –100 
and +50 mV at 0.5 mV/ms. Compared with the WT window 
current, the p.I141V window current exhibited a larger peak, 
and this peak was shifted toward more negative potentials 
(Figure 3F; Figure IC and ID in the Data Supplement).
The Importance of the p.I141 Residue on Na
v
1.5 
Channel Function
The isoleucine 141 (I141) amino acid is highly conserved across 
species- and voltage-gated sodium channels isoforms (Fig-
ure 1C and 1D). The importance of the p.I141 position on Na
v
1.5 
function was investigated by mutating the nearest and highly 
conserved isoleucine 137 to valine. Interestingly, this particular 
substitution (p.I137V) did not modify any of the Na
v
1.5 channel 
properties investigated (Figure II in the Data Supplement).
Table 2. Clinical Data of Family Members Carrying the Nav1.5 p.I141V Mutation
Family 
Member 
No.
Age  
2013 Sex
Exercise- 
Induced 
PVCs
Syncopal 
Spells
Ectopic Atrial 
Rhythm
Atrial 
Fibrillation
Threshold Heart 
Rate per Minute 
for PVCs
Number 
of PVCs 
During ET
Longest 
Salvo of 
PVCs (beats)
Total 
No. of 
PVC/24 h
Treatment at the 
Last Follow-Up 
Visit 2013
II-2 80 F Positive No + Paroxysmal 93 231 3 1 715 Metoprolol  
47.5 mg
II-4 77 M Positive No − Chronic 110 100 2 11 439 Bisoprolol 5 mg
II-7 74 M Positive No + … 90 83 4 241 Bisoprolol 2.5 
mg
II-10 70 F Positive No + … 77 219 8 12 470 Propranolol  
40 mg BID
II-12 65 F Positive No + Chronic 74 483 3 1 399 Amiodarone  
200 mg,
Bisoprolol  
5 mg BID
II-14 61 F Positive No − Paroxysmal 126 630 8 5 601 Metoprolol 
142.5+47.5 mg
III-1 61 M Negative No + … N/A 6 1 187 None
III-3 * M Positive No − Atrial flutter 95 492 2 N/A Died in 2005
III-5 52 F Positive Yes + … 84 508 5 1 646 Metoprolol  
47.5 mg BID
III-9 50 M Positive Yes + Chronic 108 637 5 336 Bisoprolol  
7.5 mg BID
III-11 48 F Positive Yes + … 120 346 6 1 130 Bisoprolol  
2.5 mg b.i.d
III-17 37 M Negative No + … - 1 1 3 None
III-19 34 F Positive No − … 104 540 3 9 925 None
IV-1 35 M Positive No − … 105 352 2 N/A None
IV-3 31 M Negative No − … N/A 4 1 N/A None
IV-7 33 M Positive No + … 108 441 2 11 Bisoprolol  
2.5 mg BID
IV-13 4 M N/A No − … N/A N/A N/A 4 None
IV-14 11 M Negative No + … N/A 7 2 1 210 None
IV-15 9 F N/A No − … N/A N/A N/A 4 None
V-1 2 M N/A No N/A N/A N/A N/A N/A N/A None
ET indicates exercise stress test; N/A, not available; and PVC, premature ventricular complex.
*Deceased.
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Atrial, Ventricular, and Purkinje Cell Action 
Potential and Conduction Modeling
To investigate the functional consequences of the cardiac 
hyperexcitability because of the p.I141V mutation of Na
v
1.5, 
we incorporated the p.I141V Na
v
1.5 properties observed 
experimentally into the atrial Courtemanche–Ramirez–Nattel, 
the ventricular TNNP, and the Purkinje Stewart–Aslanidi–
Noble–Noble–Boyett–Zhang cell models. The INa formula-
tions in all models were modified to reproduce the biophysical 
changes caused by the p.I141V mutation (see Methods and 
Figure 4A–4C). In the INa formulations of all models, the 
effects of the p.I141V mutation were simulated by shifting the 
voltage dependence of the steady state equilibrium m∞ and 
the time constant τ
m
 of the m gates by an equal amount to reca-
pitulate the shift of the steady state activation curve and the 
acceleration of activation and by shifting the voltage depen-
dence of the closing rate constant βh of the h gate to recapitu-
late the acceleration of fast inactivation with no change in the 
recovery from inactivation. The j gate was left unchanged. The 
formulations used are summarized in Table 1.
Simulations were run using the 3 cell models for WT, using 
both heterozygous and homozygous p.I141V genotypes, and the 
strength–duration curves were constructed. In the 3 models, a lower 
excitation threshold for action potential generation (pacing rates, 1 
and 2.5 Hz for the atrial and ventricular models and 2.5 Hz for the 
Purkinje model) was observed in the homozygous and heterozy-
gous p.I141V genotypes compared with the WT (Figure 4D–4I) 
Interestingly, at both pacing rates, the strength–duration curve for 
Table 3. Electrocardiographic Parameters at Rest During the 
Initial Evaluation in 2002 to 2003
SCN5A-positive, 
n=12
SCN5A-negative, 
n=17 P Value
Age, y (range) 42±18 (21–69) 43±15 (17–69) NS
Sex, (male/female) 7/5 9/8 NS
Heart rate, min−1 (range) 79±9 (63–91) 66±6 (54–75) <0.001
P, ms 100±11 100±12 NS
PQ, ms 154±29 159±22 NS
QRS, ms 89±15 91±9 NS
QT, ms 378±35 390±24 NS
QTfc, ms (range) 413±24 (383–462) 401±19 (360–430) NS
Data are from subjects without medication.
NS indicates not significant.
Figure 2. Representative ECG registrations at rest and during exercise stress test. A, Ectopic atrial rhythm at rest (ECG paper speed 
50 mm/s) of family member III-1. B, Ectopic atrial rhythm during early exercise (III-11, 25 mm/s). C, Nodal rhythm during exercise (III-9, 
50 mm/s). D, First appearance of bigeminal premature ventricular complexes (PVCs) during low workload (IV-7, 25 mm/s). E, Multi-
formic PVCs and couplets during exercise (IV-7, 25 mm/s). QRS morphology vary, indicating the multiple origin of PVCs. F, Bigeminal 
PVCs and a short ventricular tachycardia during exercise (III-5, 25 mm/s).
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the heterozygous genotype was close to the curve for the homo-
zygous genotype. In the Purkinje cell model, we observed that 
the p.I141V mutation accelerates the rate of spontaneous activity, 
even in the heterozygous state (Inset Figure 4F).
Conduction velocity was investigated in fibers of 
Courtemanche–Ramirez–Nattel, TNNP, and SANNBZ cell 
models (pacing rates, as described above). As shown in 
Figure 4J–4L, the presence of the p.I141V mutation in homo-
zygous and heterozygous states accelerated atrial and ven-
tricular conduction in a similar manner at 1 and 2.5 Hz, and it 
accelerated conduction in the Purkinje fiber at 2.5 Hz.
Clinical Follow-Up
During a follow-up of 10 years, altogether 38% of 16 adult 
Na
v
1.5 p.I141V carriers have either permanent (n=4) or 
paroxysmal (n=2) atrial fibrillation. At the end of the fol-
low-up period, β-antiadrenergic medication was used by 
10 individuals, 1 of whom was also using amiodarone. An 
implantable defibrillator (ICD) was implanted in another 
tertiary care center to 1 family member (II:14) because of 
nonsustained ventricular tachycardias. Left ventricular dila-
tation or systolic heart failure was detected in none of the 
family members during follow-up. The dilated aortic root 
had not required surgical intervention in any of the cases 
during follow-up.
Another family member (III-3) died during the follow-up 3 
years after a mitral valve replacement. He had been followed 
from the age of 36 because of frequent multiformic PVCs, parox-
ysmal atrial fibrillation, and mitral valve prolapse. Perioperative 
pulmonary vein isolation was unsuccessful in eliminating AF. A 
Figure 3. Experimental effects of p.I141V mutation on Nav1.5 channel in human embryonic kidney 293 (HEK293) cells. A, Current traces 
obtained with a current/voltage protocol (see inset) from Nav1.5-WT and p.I141V transfected cells. Bold traces are the Na
+ current at –40 mV. 
B, Steady-state activation (WT, n=8; p.I141V, n =9) and inactivation curves (WT, n=6; p.I141V, n =9). Activation properties were determined 
from I/V relationships by normalizing peak INa to driving force and maximal INa. Parameters for the voltage-dependence steady state of activa-
tion and steady state of inactivation (20-ms test pulse to −10 mV after a 500 ms conditioning prepulse) are summarized in Table in the Data 
Supplement. C, Sodium current time-to-peak values were used to evaluate the activation kinetics (WT, n=8; p.I141V, n =9). D, Fast inactiva-
tion time constants were measured by fitting the inactivation phase of the Na+ current to a single exponential equation for WT and p.I141V 
(WT, n=8; p.I141V, n =9). For C and D, a 2-way ANOVA test followed by a Bonferroni correction was used to compare point-by-point the 
measured activation and inactivation: ***P<0.001 vs WT. E, Recovery from fast inactivation was measured using the inset twin-pulse proto-
col (WT, n=5; p.I141V, n =7). F, Averaged normalized WT (n=13) and p.I141V (n=14) tetrodotoxin-sensitive window currents obtained with a 
300 ms depolarizing-voltage ramp from −100 and +50 mV (0.5 mV/ms), normalized to the peak current at −20 mV recorded in the same cell. 
Represented in panel F are the averaged normalized window current traces at the potential range between −80 and +10 mV.
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ventricular pacemaker was implanted and atrioventricular node 
ablation was performed resulting in temporary atrioventricular 
block. During follow-up, the patient experienced a syncopal 
spell 3 times. A month later, sudden cardiac arrest occurred at 
home during stressful conditions; patient was resuscitated from 
ventricular fibrillation but died few days later.
Additionally, we repeated ETs to all family members (n=21, 
including both mutation carriers and family members not car-
rying the Na
v
1.5 p.I141V mutation) whose ET was normal at 
the first examination. In the follow-up test, 3 individuals (V-7, 
III-11, and II-7) showed ≥50 PVCs at the age of 31, 45, and 69 
years, respectively. They were all carrying the Na
v
1.5 p.I141V 
mutation.
The ambulatory 24-hour ECG recording was performed at 
the end of follow-up period in 14 Na
v
1.5 p.I141V mutation 
carriers to assess the burden of AF. This revealed 1 additional 
patient (II:14) with AF, which would not have been diagnosed 
during ETs. At resting heart rates, PVCs were absent or their 
frequency was low in most Na
v
1.5 p.I141V mutation carri-
ers but their incidence increased concomitantly with physical 
activity and increasing sinus rate as illustrated in Figure III in 
the Data Supplement.
Figure 4. Effects of the p.I141V mutation on INa properties, excitability, and conduction velocity in the human atrial (CRN [Courtemanche–
Ramirez–Nattel]), the ventricular (TNNP [Tusscher–Noble–Noble–Panfilov]), and the Stewart–Aslanidi–Noble–Noble–Boyett–Zhang (SAN-
NBZ) models. A–C, Steady state activation (m∞
3) and inactivation curves (h∞j∞) in the CRN model (LR-CRN INa formulation; A), the TNNP 
model (B), and the SANNBZ model (C). D–F, Strength–duration curves in the CRN atrial cell model (inset, zoom on the strength–duration 
curves; D), the TNNP ventricular cell model (inset, zoom of the strength-duration curves; E), and the SANNBZ Purkinje cell model (inset, 
spontaneous action potentials showing the acceleration of the spontaneous rhythm because of the p.I141V mutation; F) with WT, het-
erozygous (Het), and homozygous p.I141V genotypes (pacing rate 1 Hz and 2.5 Hz). G–I, Excitation thresholds at 2 ms stimulus duration 
in the CRN atrial AP model (G), the TNNP ventricular AP model (H), and the SANNBZ Purkinje AP model (I; pacing rate 1 Hz and 2.5 Hz). 
J–L, Conduction velocities in the atrial CRN model (J), the ventricular TNNP model (K), and the SANNBZ Purkinje model (L; pacing rate 
1 Hz and 2.5 Hz). Strength–duration curves and conduction velocities could not be established at 1 Hz in the Purkinje model because of 
the accelerated spontaneous rhythm caused by the p.I141V mutation.
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Discussion
In the present study, we describe a novel missense mutation 
in a highly conserved region of the SCN5A gene, which asso-
ciates with an autosomal dominantly inherited arrhythmic 
phenotype in a large multigenerational Finnish family. This 
phenotype is characterized by exercise-induced polymorphic 
PVCs, bigeminy, and nonsustained polymorphic ventricular 
tachycardia in structurally normal hearts. Arrhythmias disap-
pear after cessation of exercise.
The affected family members displayed widespread cardiac 
hyperexcitability features manifesting as increased sinus rate, 
atrial ectopic rhythm, and atrial and nodal tachyarrhythmias. In 
the current SCN5A-linked family, the propensity to atrial arrhyth-
mias appeared to increase with age, resulting in paroxysmal and 
eventually chronic AF in many cases. Also, the number of ven-
tricular complexes during exercise increased in some patients 
during follow-up, further supporting a progressive nature of the 
disorder. The earliest age of onset of ventricular arrhythmias 
among mutation carriers cannot be exactly determined using 
data from this single family. The youngest mutation carrier 
capable of performing an ET was 11 years. Underscoring the 
diagnostic challenge, this boy did not exert multiple polymor-
phic PVCs during the clinical ET, in spite of that, his 24-hour 
ambulatory ECG recording revealed 1210 PVCs associated with 
physical exercise. Even if it is clear that the p.I141V mutation is 
not fully penetrant, the penetrance of the PVC phenotype is high, 
reaching 81% when considering only adult mutation carriers.
Evidence for Na
v
1.5 p.I141V Causality in Exercise-
Induced Polymorphic Arrhythmias
Although sequencing 2 putative genes (RYR2 and CASQ2) in 
affected members of the current family failed to identify any 
coding mutations, whole exome sequencing revealed a pre-
viously unknown missense mutation in SCN5A, which cose-
gregated with the arrhythmic phenotype. The accumulated 
evidence strongly supports the assumption that this variant is 
indeed functional and causes arrhythmia in the family investi-
gated. First, the SCN5A gene resides in the only chromosomal 
region showing complete cosegregation with the ventricular 
arrhythmia phenotype. Second, the identified mutation results 
in an amino acid change p.I141V of the Na
v
1.5 protein, which in 
silico is predicted to be possibly damaging. Third, the mutation 
resides in a region of the SCN5A gene that is highly conserved 
between species and Na
v
 homologues. Fourth, patch-clamp 
experiments show that the introduction of the mutation causes 
hyperexcitability of the Na
v
1.5 channels. Finally, computa-
tional analyses of INa and AP in single cells imply that the bio-
physical changes caused by the p.I141V mutation both include 
an acceleration of the spontaneous depolarization rate in the 
Purkinje cell model, which is similar to what was reported for 
a multifocal ectopic Purkinje-related premature contraction–
linked p.R222Q mutation by Mann et al,2 and a reduction of 
the threshold for cardiac cell excitability.
Isoleucine in the position 141 of the Na
v
1.5 protein is highly 
conserved, not only across species, but also between Na
v
 iso-
forms. Interestingly, Na
v
1.4 p.I141V and Na
v
1.7 p.I136V muta-
tions, that are homologous to the Na
v
1.5 p.I141V mutation, have 
also been associated with hyperexcitability-dependent inherited 
disorders, that is, with myotonia and erythromelalgia.17–19 Both 
these previously described mutations induce similar modifica-
tions of the biophysical properties of the sodium voltage gated 
channels as was observed for the Na
v
1.5 p.I141V mutation in 
the current study.17,19 Taken together, these findings strongly 
support the pathogenicity of this novel SCN5A missense variant.
Gain-of-Function Mutations in Na
v
1.5 and the 
Clinical Phenotypes
Gain-of-function mutations in Na
v
1.5 have previously been 
associated with several hereditary forms of arrhythmia,20 but 
also with the more recently described multifocal ectopic Pur-
kinje-related premature contraction with cardiomyopathy, that 
is linked to the presence of the p.R222Q mutation in Na
v
1.5.2–4 
In the current study, the clinical phenotype, associating with 
the p.I141V mutation, was characterized by a distinct hyper-
excitability without evidence of conduction abnormalities 
or QT interval prolongation. Although the p.I141V and the 
p.R222Q mutation both associate with atrial arrhythmias, the 
clinical characteristics of the individuals carrying the p.I141V 
mutation differ from the phenotype described in p.R222Q-car-
riers. Although exercise provoked ventricular arrhythmias in 
p.I141V-carriers, p.R222Q-carriers typically manifest arrhyth-
mias at resting heart rates. Moreover, carriers of p.R222Q 
show frequent PVCs, with both left and right bundle-branch 
block patterns triggered from Purkinje fibers at low heart rates, 
but disappearance of PVCs during exercise, and dilated cardio-
myopathy.2,3 In p.I141V mutation carriers, the burden of PVCs 
was much lower, which may explain why they did not display 
any abnormalities in ventricular structure or contractility.
In spite of the above described dissimilarities between the 
clinical phenotypes, the differences in the cellular phenotypes 
associating with the p.I141V and p.R222Q mutations were 
more subtle. Although the p.I141V mutation did not modify 
the voltage dependence of inactivation, it did shift the activa-
tion curve to negative potentials and led to an increase and 
shift of the sodium window current. In contrast, the p.R222Q 
mutation affects the voltage dependence of both activation and 
inactivation, resulting in a negative shift of the sodium win-
dow current. To bear in mind, in vitro phenotypes observed in 
heterologous expression systems may not always reflect the 
clinical phenotypes induced by a mutation. As an example, 
although many studies have reported several varied pheno-
types associating with a SCN5A p.D1275N missense muta-
tion, for example, atrial standstill, dilated cardiomyopathy 
with conduction disease, atrial flutter/fibrillation, sick sinus 
syndrome, and ventricular dilation and dysfunction, the muta-
tion does not induce marked Na
v
1.5 dysfunction in vitro. 
However, when studied in genetically engineered mice, in 
vivo, the mutation generates extensive aberration of channel 
function,21 underscoring that functional phenotypes may be 
influenced substantially by the experimental systems used.
Overall, the complex pathways underlying the genotype–
phenotype relationship in hereditary arrhythmia syndromes are 
poorly known, and the reasons for incomplete penetrance and 
variable expressivity remain obscure.1,22 Pleiotropy has been 
associated with SCN5A mutations in particular. Although distinct 
clinical phenotypes have been ascribed to different mutations in 
the SCN5A gene, for example, LQTS, BrS, and cardiomyopathy 
by others and the present exercise-induced phenotype by us,23–29 
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some mutations also display a substantial degree of variability 
within families. For example, the affected family members of 
a large family segregating a SCN5A-1795insD presented with a 
wide array of clinical manifestations, including sinus node dys-
function, bradycardia, conduction disease, BrS, and LQTS.23,24
Mechanistic Considerations
The mutation-induced alterations of Na
v
1.5 properties and simu-
lation studies support the concept that the increase in window 
current lead to a ventricular and atrial hyperexcitability. It is 
interesting to note that administration of flecainide 2 mg/kg IV 
to patients II-10 and III-19 resulted in a significant reduction of 
PVCs during an exercise stress (from 219 and 540 to 17 and 0, 
respectively). Also, in a previous study, flecainide has been shown 
to induce a dramatic reduction in PVCs and recovery of normal 
left ventricular function in SCN5A p.R222Q mutation carriers,.2 
Although flecainide may directly act on RyR2 channels,30–32 it has 
recently been suggested that the drug may reduce sodium chan-
nel availability, which would increase the channel threshold for 
triggered activity.33 Recently, using a rat cardiomyocyte model, 
Sikkel et al34 showed that flecainide reduces calcium sparks by a 
mechanism involving reduction of INa, that is, through increased 
Ca2+ efflux via the sodium–calcium exchanger across the sar-
colemma and reduced Ca2+ concentration in the vicinity of the 
RyR2. Given these previous observations linking INa with calcium 
homeostasis, one may speculate that the mechanism whereby the 
SCN5A p.I141V may cause exercise-induced PVCs in part may 
involve alterations of intracellular calcium flux.
Conclusions
The Na
v
1.5 protein, encoded by the SCN5A gene, has previ-
ously been associated with a variety of clinical arrhythmia 
phenotypes, including congenital LQTS, BrS, and multifocal 
ectopic Purkinje-related premature contraction. The present 
study demonstrates that mutations in SCN5A also may result 
in exercise-induced polymorphic ventricular premature com-
plexes and tachycardia.
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CLINICAL PERSPECTIVE
Premature ventricular complexes constitute a diagnostic challenge because in a small proportion of patients, they may indi-
cate the risk of lethal ventricular tachycardia or fibrillation. Exercise-induced premature ventricular complexes, bigeminy, 
and ventricular tachycardias in structurally normal hearts are characteristic of the catecholaminergic polymorphic ventricu-
lar tachycardia and are associated with considerable mortality. A correct presymptomatic diagnosis by genetic testing is 
particularly valuable because lethal arrhythmias may occur in catecholaminergic polymorphic ventricular tachycardia even 
before diagnostic exercise-induced symptoms can be verified, at least in carriers with mutations of the ryanodine receptor 
type 2 gene. We demonstrate in this investigation that a mutation in the cardiac sodium channel gene SCN5A can also cause 
exercise-induced polymorphic ventricular tachycardias. Similar to catecholaminergic polymorphic ventricular tachycardia, 
physical exercise provokes premature ventricular complexes and nonsustained polymorphic ventricular tachycardia that 
disappear after cessation of exercise. Unlike in catecholaminergic polymorphic ventricular tachycardia, also the atria are 
prone to ectopic activity and tachyarrhythmias. Our findings could help the clinician to differentiate these exercise-provoked 
ventricular arrhythmias from those associated with ryanodine receptor type 2 and calsequestrin 2 mutations. Awareness of 
the potential contribution of SCN5A to inherited exercise-induced polymorphic ventricular tachyarrhythmias could facilitate 
the identification of more mutation carriers and assist in determining their prognostic significance. Patients with the exercise-
induced polymorphic ventricular arrhythmias could be tested also for the SCN5A gene, particularly if ryanodine receptor 
type 2 and calsequestrin 2 have tested negative. In general, the present study demonstrates the importance of genotypic and 
phenotypic classification of cardiac arrhythmias which have similar clinical presentations but actually may have different 
prognosis and require different therapeutic approaches.
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SUPPLEMENTAL MATERIAL  
Supplemental Table 
Supplemental figure legends 
Supplemental Figure 1. Experimental Effects of p.I141V Mutation on Nav1.5 Channel in HEK293 
Cells 
(A) Time dependence of the onset of slow inactivation was measured using the inset protocol. (B) Recovery 
from slow inactivation was measured using the inset protocol. (C) The distribution of peak window currents 
normalized to the peak current at -20mV; *p<0.05. (D) Voltage at the peak window currents; ***p<0.001.   
 
Supplemental Figure 2. Experimental Effects of p.I137V Mutation on Nav1.5 Channel in HEK293 
Cells 
(A) I/V relationship from Nav1.5-WT (n=6) and p.I137V (n=5) transfected cells. (B) Steady-state activation 
and inactivation curves from Nav1.5-WT (n=6) and p.I137V (n=5). Parameters for the voltage-dependence 
steady-state of activation and steady state of inactivation are summarized in Supplemental Table 1B. (C) 
Sodium current activation kinetics from Nav1.5-WT (n=6) and p.I137V (n=5). (D) Fast inactivation time 
constants from Nav1.5-WT (n=6) and p.I137V (n=5).   
 
Supplemental Figure 3. Sinus rate and number of PVCs per 30 seconds during 21 hour ambulatory 
ECG recording 
Patient III-5 showed 1646 PVCs during a 21-hour ambulatory ECG recording. The upper panel shows the 
sinus rate and the lower panel illustrates the rate dependence of PVCs, the number of which increases upon 
physical exercise. 
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